Correlation Engine 2.0
Clear Search sequence regions


Respiratory distress syndrome (RDS) is the leading cause of neonatal morbidity and mortality in premature infants. It is caused by surfactant deficiency and lung immaturity. Lucinactant is a synthetic surfactant containing sinapultide, a bioengineered peptide mimic of surfactant-associated protein B. A meta-analysis of clinical trials demonstrates that lucinactant is as effective as animal-derived surfactants in preventing RDS in premature neonates, and in vitro studies suggest it is more resistant to oxidative and protein-induced inactivation. Its synthetic origin confers lower infection and inflammation risks as well other potential benefits, which may make lucinactant an advantageous alternative to its animal-derived counterparts, which are presently the standard treatment for RDS.

Citation

Brian K Jordan, Steven M Donn. Lucinactant for the prevention of respiratory distress syndrome in premature infants. Expert review of clinical pharmacology. 2013 Mar;6(2):115-21

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 23473590

View Full Text